Shattuck Labs is advancing the standard of care in inflammatory diseases through innovation, developing a first-in-class DR3 blocking antibody for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases
Shattuck Labs is advancing the standard of care in inflammatory diseases through innovation, developing a first-in-class DR3 blocking antibody for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases.